Valeria Saraiba-Rabanales
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valeria Saraiba-Rabanales has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anita Deswal
Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication Efstratios Koutroumpakis
Department of Cardiology University of Texas MD Anderson Cancer Center 77030 Houston TX USA
1 shared publicationEmily Wang
Department of Cardiology University of Texas MD Anderson Cancer Center 77030 Houston TX USA
1 shared publication- Enrique Soto-Perez-De-Celis
Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, USA
1 shared publication Hyeon-Ju Ali
1 shared publicationKeila C. Ostos-Mendoza
Department of Cardiology University of Texas MD Anderson Cancer Center 77030 Houston TX USA
1 shared publication
Latest Publications
- 12 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (2) , 341-347
Trends in Cervical Cytology Test Reports and Cervical Dysplasia Severity according to Social Deprivation in Mexico (2013–2019): An Analysis of a National Database
Background: Cervical cancer is a leading cause of cancer-related mortality in women living in low- and middle-income countries such as Mexico. Preventive and screening programs are often inaccessible to socially deprived populations, whose limited access to timely diagnosis and treatment reduces the chance of detecting premalignant lesions early. Methods: Cervical malignant and premalignant lesion positivity rates were analyzed from 2013 to 2016 using the Bethesda system, whereas human papillomavirus (HPV) positivity rates were analyzed from 2017 to 2019. Both were stratified according to state-level Social Deprivation Indices in Mexico, published by the National Council for the Evaluation of Social Development Policy. The data originated from the four main healthcare providers in Mexico. Data processing and statistical analyses were performed using Joinpoint Regression Software and SPSS version 25. Results: Positivity rates for dysplasia and atypia varied across social deprivation levels. A downward trend in premalignant lesion positivity rates was observed. This varied across social deprivation groups, with differing annual percentage changes (APC). The greatest decrease occurred in high-grade cervical intraepithelial dysplasia (CIN 2–3) in states with very high social deprivation, with an estimated APC of −22.1% (−30% to −14.7%; P = 0.001). HPV positivity by PCR ranged from 11% to 24% between 2017 and 2019. The estimated APC for invasive cervical carcinoma was −22.3% [95% confidence interval (CI); −54.4% to 19.8%], which was not statistically significant (P = 0.223). Conclusions: Our study highlights a decline in cervical dysplasia positivity rates. These declines were uneven across social deprivation levels. Impact: Reducing health inequities is essential to prevent, detect, and treat cervical cancer and its precursors.
- 12 December 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (2) , 341-347
Trends in Cervical Cytology Test Reports and Cervical Dysplasia Severity according to Social Deprivation in Mexico (2013–2019): An Analysis of a National Database
Background: Cervical cancer is a leading cause of cancer-related mortality in women living in low- and middle-income countries such as Mexico. Preventive and screening programs are often inaccessible to socially deprived populations, whose limited access to timely diagnosis and treatment reduces the chance of detecting premalignant lesions early. Methods: Cervical malignant and premalignant lesion positivity rates were analyzed from 2013 to 2016 using the Bethesda system, whereas human papillomavirus (HPV) positivity rates were analyzed from 2017 to 2019. Both were stratified according to state-level Social Deprivation Indices in Mexico, published by the National Council for the Evaluation of Social Development Policy. The data originated from the four main healthcare providers in Mexico. Data processing and statistical analyses were performed using Joinpoint Regression Software and SPSS version 25. Results: Positivity rates for dysplasia and atypia varied across social deprivation levels. A downward trend in premalignant lesion positivity rates was observed. This varied across social deprivation groups, with differing annual percentage changes (APC). The greatest decrease occurred in high-grade cervical intraepithelial dysplasia (CIN 2–3) in states with very high social deprivation, with an estimated APC of −22.1% (−30% to −14.7%; P = 0.001). HPV positivity by PCR ranged from 11% to 24% between 2017 and 2019. The estimated APC for invasive cervical carcinoma was −22.3% [95% confidence interval (CI); −54.4% to 19.8%], which was not statistically significant (P = 0.223). Conclusions: Our study highlights a decline in cervical dysplasia positivity rates. These declines were uneven across social deprivation levels. Impact: Reducing health inequities is essential to prevent, detect, and treat cervical cancer and its precursors.
- Open Access
- 28 February 2025
- Published by OAE Publishing Inc. in The Journal of Cardiovascular Aging
- Vol. 5 (1)
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Background: Immune checkpoint inhibitors (ICIs) have changed the landscape in oncology, providing effective cancer management for a growing population. However, by promoting an immunological attack on cancer cells, healthy cells may be harmed in the process. Increased awareness of ICI-associated myocarditis (ICIMy) as one of the most fatal immune-related adverse events has led to efforts to improve the diagnosis and treatment of this condition. The purpose of this review is to summarize the current state of knowledge regarding ICIMy. Methods: We performed a literature search in Pubmed and Scopus with the relevant keywords, screened the titles and abstracts of the results, and reviewed the selected publications using pre-established criteria. Main findings: Although ICIMy’s cumulative incidence is below 0.5% in clinical trials, real-world data reveal a higher incidence of up to 4%. Underlying pathophysiologic mechanisms include T cell clonal expansion, molecular mimicry, and increased inflammatory cytokine signaling pathways leading to ICIMy. The clinical presentation can vary from asymptomatic to fulminant cardiac death and is often accompanied by musculoskeletal adverse events. Emerging diagnostic tools with prognostic value include global longitudinal strain assessment and multiple PET-CT modalities. The mainstay of treatment includes holding the immunotherapy, prompt high-dose methylprednisolone, and close cardiovascular observation. Fulminant and refractory cases benefit from additional immunomodulatory therapies. Principal conclusions: Although ICIMy is a rare adverse event, its non-specific presentation warrants a high level of suspicion. Once ICIMy is considered a likely diagnosis, immunomodulatory therapies should be initiated promptly.
- 28 February 2025
- Published by OAE Publishing Inc. in The Journal of Cardiovascular Aging
- Vol. 5 (1)
Open AccessImmune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Background: Immune checkpoint inhibitors (ICIs) have changed the landscape in oncology, providing effective cancer management for a growing population. However, by promoting an immunological attack on cancer cells, healthy cells may be harmed in the process. Increased awareness of ICI-associated myocarditis (ICIMy) as one of the most fatal immune-related adverse events has led to efforts to improve the diagnosis and treatment of this condition. The purpose of this review is to summarize the current state of knowledge regarding ICIMy. Methods: We performed a literature search in Pubmed and Scopus with the relevant keywords, screened the titles and abstracts of the results, and reviewed the selected publications using pre-established criteria. Main findings: Although ICIMy’s cumulative incidence is below 0.5% in clinical trials, real-world data reveal a higher incidence of up to 4%. Underlying pathophysiologic mechanisms include T cell clonal expansion, molecular mimicry, and increased inflammatory cytokine signaling pathways leading to ICIMy. The clinical presentation can vary from asymptomatic to fulminant cardiac death and is often accompanied by musculoskeletal adverse events. Emerging diagnostic tools with prognostic value include global longitudinal strain assessment and multiple PET-CT modalities. The mainstay of treatment includes holding the immunotherapy, prompt high-dose methylprednisolone, and close cardiovascular observation. Fulminant and refractory cases benefit from additional immunomodulatory therapies. Principal conclusions: Although ICIMy is a rare adverse event, its non-specific presentation warrants a high level of suspicion. Once ICIMy is considered a likely diagnosis, immunomodulatory therapies should be initiated promptly.